Search alternatives:
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
significant case » significant cause (Expand Search), significant based (Expand Search), significant change (Expand Search)
nn decrease » _ decrease (Expand Search), mean decrease (Expand Search), gy decreased (Expand Search)
case based » made based (Expand Search), game based (Expand Search), rate based (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
141
-
142
A randomized trial of a behavioral intervention to decrease hospital length of stay by decreasing bedrest
Published 2020“…In the multivariate analysis, neither the behavioral intervention nor the provision of a recliner chair was associated with a significant decrease in length of stay or increase in functional status as measured by the ‘6-Clicks’ functional score.…”
-
143
-
144
-
145
Significantly Enriched Pathways.
Published 2025“…Pathway analysis revealed a marked decrease in expression within certain key metabolic pathways (such as the one-carbon pool by folate) in the NAFLD group, while expression in DNA repair-related pathways (such as non-homologous end joining) was significantly increased. …”
-
146
-
147
The base case analysis.
Published 2025“…</p><p>Results</p><p>In the base-case scenario, adding benmelstobart and anlotinib to chemotherapy increased QALYs by 0.34 at an additional cost of $24,684.07, yielding an ICER of $71,559.84 per QALY. …”
-
148
-
149
Base-case results.
Published 2025“…One-way and probabilistic sensitivity analyses were conducted to estimate the robustness of the model results,</p><p>Results</p><p>In base-case analysis, compared with toripalimab plus chemotherapy and chemotherapy alone, ITH-testing directed therapy could bring additional 0.14 QALYs and 0.29 QALYs, with marginal costs of $3750.75 and $7778.18, resulting in the ICER of $27,353.27/QALY and $26,461.46/QALY, respectively, which lower than the Chinese willingness-to-pay (WTP) threshold. …”
-
150
-
151
-
152
Base-case results.
Published 2024“…Clinical findings have showed that deprescribing service significantly decreased inappropriate PPIs utilization. …”
-
153
-
154
-
155
-
156
Synaptopathy at IHC-SGN synapses decreases the peak of the CAP significantly, without changes to peak latency and width.
Published 2021“…<p>(A) Sound-evoked CAPs of SGN fiber populations with different synaptopathy scenarios at 70dB SPL, averaged over 50 simulations. …”
-
157
-
158
-
159
-
160